Role of microRNA in the pathogenesis of malignant lymphoma

Cancer Science

Volumn 104, Issue 7, 2013, Pages 801-809

  Tagawa, Hiroyuki ^a   Ikeda, Sho ^a   Sawada, Kenichi ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; MICRORNA; ONCOPROTEIN; UNTRANSLATED RNA;

BURKITT LYMPHOMA; C13ORF25 GENE; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; DLEU2 GENE; EXPRESSED SEQUENCE TAG; GENE; GENE OVEREXPRESSION; HUMAN; IMMUNOGLOBULIN GENE; LARGE CELL LYMPHOMA; LYMPHOMA; MALIGNANT TRANSFORMATION; NK T CELL LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOGENESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA; MICRORNAS;

EID: 84880742480     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12160     Document Type: Review

References (83)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
2. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
3. Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in Cancer. Cancer Res 2013; 73: 473-7.
4. Migliazza A, Bosch F, Komatsu H et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2098-104.
5. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
6. Metzler M, Wilda M, Busch K et al. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosom Cancer 2004; 39: 167-9.
7. Kluiver J, van den Berg A, de Jong D et al. Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene 2007; 26: 3769-76.
8. Ota A, Tagawa H, Karnan S et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004; 64: 3087-95.
9. Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
10. Eiring AM, Harb JG, Neviani P et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010; 140: 652-65.
11. Tagawa H, Seto M. A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia 2005; 19: 2013-6.
12. Tagawa H, Karnan S, Suzuki R et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 1348-58.
13. Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M. Synergistic action of microRNA-17 polycistron and MYC in aggressive cancer development. Cancer Sci 2007; 98: 1482-90.
14. He L, Thomson JM, Hemann MT et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-33.
15. O'Donnell KA, Wentzel EA, Zelller KI, Dang CV, Mendell JT. C-Myc-regulated microRNas modulate E2F1 expression. Nature 2005; 435: 839-43.
16. Dews M, Homayouni A, Yu D et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38: 1060-65.
17. Ventura A, Young AG, Winslow MM et al. Targeted deletion reveals essential and overlapping functions of the miR-17~92 family of miRNA clusters. Cell 2008; 132: 875-86.
18. Xiao C, Srinivasan L, Calado DP et al. Lymphoproliferative disease and autoimmunity in mice with elevated miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-14.
19. Inomata M, Tagawa H, Guo Y-M et al. MicroRNA-17-92 downregulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 2009; 113: 396-402.
20. Olive V, Bennett MJ, Walker JC et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009; 23: 2839-49.
21. Mu P, Han YC, Betel D et al. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 2009; 23: 2806-11.
22. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
23. Lenz G, Wright GW, Emre NC et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008; 105: 13520-25.
24. Eis PS, Tam W, Sun L et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005; 102: 3627-32.
25. Muramatsu M, Kinoshita K, Fagarasan S et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102: 553-63.
26. Malumbres R, Sarosiek KA, Cubedo E et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009; 113: 3754-64.
27. Montes-Moreno S, Martinez N, Sanchez-Espiridión B et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood 2011; 118: 1034-40.
28. Alencar AJ, Malumbres R, Kozloski GA et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011; 17: 4125-35.
29. Kluiver J, Poppema S, de Jong D et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005; 207: 243-9.
30. - anaplastic large-cell lymphoma. Proc Natl Acad Sci USA 2010; 107: 16228-33.
31. Desjobert C, Renalier MH, Bergalet J et al. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood 2011; 117: 6627-37.
32. Robbiani DF, Bothmer A, Callen E et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 2008; 135: 1028-38.
33. Dorsett Y, McBride KM, Jankovic M et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 2008; 8: 630-38.
34. Lenze D, Leoncini L, Hummel M et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 2011; 25: 1869-76.
35. Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH. Introduction and over review of the classification of the lymphoid neoplasms. In: Swerdloe AH, Campo E, Harris NL, Jaffe ES, Stein H, Thiele J, Vardiman JW, eds. World health classification of tumors. Pathology & Genetics of tumors of haematopoietic and lymphoid tissues. Washington, Lyon: IARC press, 2008; 158-78.
36. Hadzidimitriou A, Agathangelidis A, Darzentas N et al. Is there a role for antigen selection in mantle cell lymphoma? Imunogenetic support from a series of 807 cases. Blood 2011; 118: 3088-95.
37. Beà S, Salaverria I, Armengol L et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009; 113: 3059-69.
38. Zhao JJ, Lin J, Lwin T et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115: 2630-9.
39. Zhang X, Zhao X, Fiskus W et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell 2012; 22: 506-23.
40. Navarro A, Beà S, Fernández V et al. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in mantle cell lymphomas. Cancer Res 2009; 69: 7071-8.
41. Di Lisio L, Gómez-López G, Sánchez-Beato M et al. Mantle cell lymphoma: transcriptional regulation by microRNAs. Leukemia 2010; 24: 1335-42.
42. Teshima K, Nara M, Watanabe A et al. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma. Oncogene 2013; in press.
43. Chen RW, Bemis LT, Amato CM et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 2008; 112: 822-9.
44. Nakashima Y, Tagawa H, Suzuki R et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T lymphoma, nasal type. Genes Chromosom Cancer 2005; 19: 247-55.
45. Iqbal J, Kucuk C, Deleeuw RJ et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009; 23: 1139-51.
46. Karube K, Nakagawa M, Tsuzuki S et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 2011; 118: 3195-204.
47. Yamanaka Y, Tagawa H, Takahashi N et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 2009; 114: 3265-75.
48. Watanabe A, Tagawa H, Yamashita J et al. The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia 2011; 25: 1324-34.
49. Horn S, Endl E, Fehse B et al. Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3b signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia 2004; 18: 1839-49.
50. Freeburn RW, Wright K, Burgess SJ et al. Evidence that SHIP-1 contributes to phosphatidilinositol 3, 4, 5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. J Immunol 2002; 169: 5441-50.
51. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 2009; 106: 7113-18.
52. Yin Q, McBride J, Fewell C et al. MicroRNA-155 is an Epsein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J Virol 2008; 82: 5295-306.
53. Bellon M, Lepelletier Y, Hermine O, Nicot C. Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood 2009; 113: 4914-417.
54. Yamagishi M, Nakano K, Miyake A et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell 2012; 21: 121-35.
55. Oshiro A, Tagawa H, Ohshima K et al. Identification of subtype-specific genomic alteration of aggressive type of adult T cell lymphoma/leukemia. Blood 2006; 107: 4500-507.
56. Wang W, Corrigan-Cummins M, Hudson J et al. MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica 2012; 97: 586-94.
57. Karube K, Guo Y, Suzumiya J et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 2007; 109: 3076-9.
58. Leich E, Zamo A, Horn H et al. MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood 2011; 118: 5550-58.
59. Liu TY, Chen SU, Kuo SH, Cheng AL, Lin CW. E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response. Mod Pathol 2010; 23: 1507-517.
60. Craig VJ, Cogliatti SB, Imig J et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011; 117: 6227-36.
61. Arribas AJ, Campos-Martín Y, Gómez-Abad C et al. Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. Blood 2012; 119: e9-e21.
62. Ruiz-Ballesteros E, Mollejo M, Mateo M, Algara P, Martinez P, Piris MA. MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia 2007; 21: 2547-9.
63. Bouteloup M, Verney A, Rachinel N et al. MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol 2012; 156: 279-81.
64. Peveling-Oberhag J, Crisman G, Schmidt A et al. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 2012; 26: 1654-62.
65. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467: 86-90.
66. Klein U, Lia M, Crespo M et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28-40.
67. Nie K, Gomez M, Landgraf P et al. microRNA-mediated downregulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol 2008; 173: 242-52
68. Zhang X, Chen X, Lin J et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012; 3: 300-308.
69. Ballabio E, Mitchell T, van Kester MS et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010; 116: 1105-13.
70. Gibcus JH, Tan LP, Harms G et al. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia 2009; 11: 167-76.
71. Rao E, Jiang C, Ji M et al. The miRNA-17~92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2012; 26: 1064-72.
72. Fassina A, Marino F, Siri M et al. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest 2012; 92: 1574-82.
73. Navarro A, Gaya A, Martinez A et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood 2008; 111: 2825-32.
74. Lawrie CH, Soneji S, Marafioti T et al. MicroRNA expression distinguishes between germinal center B-cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 2007; 121: 1156-61.
75. Lawrie CH, Saunders NJ, Soneji S et al. MicroRNA expression in lymphocyte development and malignancy. Leukemia 2008; 22: 1440-46.
76. Navarro A, Diaz T, Martinez A et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 2009; 114: 2945-51.
77. Motsch N, Alles J, Imig J et al. MicroRNA profiling of Epstein-Barr virus-associated NK/T-cell lymphomas by deep sequencing. PLoS ONE 2012; 7: e42193.
78. Saito Y, Suzuki H, Tsugawa H et al. Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS ONE 2012; 7: e47396.
79. Paik JH, Jang JY, Jeon YK et al. MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res 2011; 17: 4761-71.
80. Monsálvez V, Montes-Moreno S, Artiga MJ et al. MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. Mod Pathol 2013; 26: 171-81.
81. Kluiver J, Haralambieva E, de Jong D et al. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosom Cancer 2006; 45: 147-53.
82. Ralfkiaer U, Hagedorn PH, Bangsgaard N et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011; 118: 5891-900.
83. Valleron W, Ysebaert L, Berquet L et al. Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. Blood 2012; 120: 3997-4005.